Prevalence and Management of Hypokalemia in Peritoneal Dialysis Patients in Qatar
Joint Authors
Hamad, Abdullah
Hussain, Mohammed Ezzat
Elsanousi, Shaza
Ahmed, Hanaa
Navalta, Luzvi
Lonappan, Vimala
Alali, Fadwa
Source
International Journal of Nephrology
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-12-18
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Introduction.
Hypokalemia is common in patients undergoing peritoneal dialysis (PD).
It is associated with increased cardiovascular and all-cause mortality.
Treatment usually includes oral potassium supplements, which are poorly tolerated.
Our aim was to evaluate the prevalence of hypokalemia in PD patients in Qatar and to improve treatment measures.
Methods.
All PD patients in Qatar with persistent hypokalemia and on potassium supplement were included.
We performed a root cause analysis, and a management pathway was created.
We collected data before (Period 1) and after (Period 2) implementation of the new pathway.
Results.
A total of 143 patients with a mean age of 54 years (range 21–82 years) were included in the study.
Initial results of Period 1 showed hypokalemia in 48 patients (34%); of these, 14 (29%) had hypomagnesemia.
Hypokalemia resolved in 10 of the patients after correction of their hypomagnesemia.
The remaining 4 patients continued to require potassium supplementation despite correction of their hypomagnesemia.
We started spironolactone (25 mg daily) in 13 of the hypokalemia patients.
After 3 months, their mean serum potassium level improved from 3.2 ± 0.3 mmol/L to 3.9 ± 0.4 mmol/L (p<0.001), and the prevalence of patients with persistent hypokalemia decreased from 36% to 21% (statistically significant with p= 0.006).
No episodes of hypotension or hyperkalemia were observed.
Only 1 patient developed mild gynecomastia without discontinuation of the medications.
Conclusion.
Our study showed that hypokalemia is a prevalent problem in PD patients in Qatar.
Hypomagnesemia is a significant contributing factor to hypokalemia in PD and correcting it leads to improvement of hypokalemia.
Addition of spironolactone is safe and effective in treating hypokalemia.
Implementing a holistic pathway led to a significant improvement in hypokalemia prevalence in PD patients.
American Psychological Association (APA)
Hamad, Abdullah& Hussain, Mohammed Ezzat& Elsanousi, Shaza& Ahmed, Hanaa& Navalta, Luzvi& Lonappan, Vimala…[et al.]. 2019. Prevalence and Management of Hypokalemia in Peritoneal Dialysis Patients in Qatar. International Journal of Nephrology،Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1166472
Modern Language Association (MLA)
Hamad, Abdullah…[et al.]. Prevalence and Management of Hypokalemia in Peritoneal Dialysis Patients in Qatar. International Journal of Nephrology No. 2019 (2019), pp.1-6.
https://search.emarefa.net/detail/BIM-1166472
American Medical Association (AMA)
Hamad, Abdullah& Hussain, Mohammed Ezzat& Elsanousi, Shaza& Ahmed, Hanaa& Navalta, Luzvi& Lonappan, Vimala…[et al.]. Prevalence and Management of Hypokalemia in Peritoneal Dialysis Patients in Qatar. International Journal of Nephrology. 2019. Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1166472
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1166472